Linong Ji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/123395/publications.pdf

Version: 2024-02-01

341 papers	12,893 citations	50276 46 h-index	31849 101 g-index
350 all docs	350 docs citations	350 times ranked	14809 citing authors

#	Article	IF	Citations
1	Prevalence of Diabetes among Men and Women in China. New England Journal of Medicine, 2010, 362, 1090-1101.	27.0	2,685
2	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 2016, 39, 861-877.	8.6	718
3	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 546-550.	11.4	680
4	Standards of medical care for type 2 diabetes in China 2019. Diabetes/Metabolism Research and Reviews, 2019, 35, e3158.	4.0	404
5	Standards of care for type 2 diabetes in China. Diabetes/Metabolism Research and Reviews, 2016, 32, 442-458.	4.0	236
6	Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice, 2015, 110, 26-37.	2.8	216
7	Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes and Endocrinology,the, 2014, 2, 935-943.	11.4	210
8	Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study). Diabetes, 2013, 62, 543-550.	0.6	204
9	New Insulin Delivery Recommendations. Mayo Clinic Proceedings, 2016, 91, 1231-1255.	3.0	200
10	Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ: British Medical Journal, 2018, 360, j5295.	2.3	193
11	Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients. American Journal of Medicine, 2013, 126, 925.e11-925.e22.	1.5	174
12	Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes and Endocrinology,the, 2016, 4, 115-124.	11.4	173
13	A Genome-Wide Association Study Identifies GRK5 and RASGRP1 as Type 2 Diabetes Loci in Chinese Hans. Diabetes, 2013, 62, 291-298.	0.6	166
14	Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics, 2015, 37, 225-241.e8.	2.5	155
15	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care, 2020, 43, 1695-1703.	8.6	147
16	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64, 275-287.	6.3	140
17	Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study. Clinical Therapeutics, 2014, 36, 84-100.e9.	2.5	139
18	Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes and Endocrinology,the, 2019, 7, 9-11.	11.4	138

#	Article	IF	Citations
19	Impact of Waist Circumference and Body Mass Index on Risk of Cardiometabolic Disorder and Cardiovascular Disease in Chinese Adults: A National Diabetes and Metabolic Disorders Survey. PLoS ONE, 2013, 8, e57319.	2.5	130
20	Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial. Diabetes Therapy, 2017, 8, 293-307.	2.5	128
21	Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health, 2013, 13, 602.	2.9	117
22	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Metaâ€Analysis. Obesity, 2018, 26, 70-80.	3.0	109
23	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 172-183.	2.0	102
24	Epidemic T2DM, early development and epigenetics: implications of the Chinese Famine. Nature Reviews Endocrinology, 2018, 14, 738-746.	9.6	100
25	Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Technology and Therapeutics, 2015, 17, 35-42.	4.4	99
26	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Journal of Diabetes Research, 2015, 2015, 1-9.	2.3	87
27	Sex- and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities. Nature Aging, 2021, 1, 87-100.	11.6	86
28	Depression in <scp>C</scp>hinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. Journal of Diabetes, 2015, 7, 800-808.	1.8	81
29	Efficacy and safety of exenatide onceâ€weekly vs exenatide twiceâ€daily in <scp>A</scp>sian patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2013, 4, 53-61.	2.4	72
30	Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial. PLoS ONE, 2013, 8, e56703.	2.5	71
31	Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone, 2020, 130, 115121.	2.9	71
32	Investigation of 2 Models to Set and Evaluate Quality Targets for Hb A1c: Biological Variation and Sigma-Metrics. Clinical Chemistry, 2015, 61, 752-759.	3.2	69
33	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
34	NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?â€"Results From NHANES III. Frontiers in Medicine, 2021, 8, 693507.	2.6	67
35	The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Endocrine, 2018, 62, 299-306.	2.3	65
36	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. Diabetes Research and Clinical Practice, 2019, 151, 20-32.	2.8	63

#	Article	IF	Citations
37	Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact. Diabetes Technology and Therapeutics, 2017, 19, 61-67.	4.4	61
38	Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes and Endocrinology,the, 2018, 6, 627-636.	11.4	61
39	Associations between metformin use and vitamin B₁₂ levels, anemia, and neuropathy in patients with diabetes: a metaâ€analysis. Journal of Diabetes, 2019, 11, 729-743.	1.8	61
40	Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus. Medicine (United States), 2020, 99, e19052.	1.0	58
41	Association between socioeconomic status and metabolic control and diabetes complications: a cross-sectional nationwide study in Chinese adults with type 2 diabetes mellitus. Cardiovascular Diabetology, 2016, 15, 61.	6.8	56
42	Measuring depressive symptoms using the Patient Health Questionnaire-9 in Hong Kong Chinese subjects with type 2 diabetes. Journal of Affective Disorders, 2013, 151, 660-666.	4.1	54
43	DPPâ€4 inhibitors and risk of infections: a metaâ€analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2016, 32, 391-404.	4.0	54
44	First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. Journal of Diabetes, 2011, 3, 208-216.	1.8	53
45	ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. Diabetes Care, 2022, 45, 261-266.	8.6	53
46	Comparisons of weight changes between sodiumâ€glucose cotransporter 2 inhibitors treatment and glucagonâ€like peptideâ€1 analogs treatment in type 2 diabetes patients: A metaâ€analysis. Journal of Diabetes Investigation, 2017, 8, 510-517.	2.4	51
47	A Multicenter Evaluation of the Performance and Usability of a Novel Glucose Monitoring System in Chinese Adults With Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 290-295.	2.2	51
48	No disparity of the efficacy and allâ€cause mortality between Asian and nonâ€Asian type 2 diabetes patients with sodiumâ€“glucose cotransporter 2 inhibitors treatment: A metaâ€analysis. Journal of Diabetes Investigation, 2018, 9, 850-861.	2.4	49
49	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. Journal of Diabetes and Its Complications, 2017, 31, 1188-1196.	2.3	46
50	Observational <scp>R</scp>egistry of <scp>B</scp>asal <scp>I</scp>nsulin <scp>T</scp>reatment (<scp>ORBIT</scp>) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: <scp>R</scp>ealâ€life use of basal insulin in <scp>C</scp>hina. Diabetes, Obesity and Metabolism, 2017, 19, 822-830.	4.4	45
51	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics, 2017, 19, 391-399.	4.4	45
52	Efficacy and safety of onceâ€weekly semaglutide versus onceâ€daily sitagliptin as addâ€on to metformin in patients with type 2 diabetes in <scp>SUSTAIN China</scp>: A 30â€week, doubleâ€blind, phase 3a, randomized trial. Diabetes, Obesity and Metabolism, 2021, 23, 404-414.	4.4	45
53	BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. Journal of Diabetes and Its Complications, 2014, 28, 470-476.	2.3	43
54	Metaâ€analysis and critical review on the efficacy and safety of alphaâ€glucosidase inhibitors in Asian and nonâ€Asian populations. Journal of Diabetes Investigation, 2018, 9, 321-331.	2.4	43

#	Article	IF	Citations
55	Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey. Medical Science Monitor, 2015, 21, 1440-1446.	1.1	41
56	Prevalence of microvascular diseases among tertiary care Chinese with early versus late onset of type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 32-37.	2.3	40
57	The effect of diabetes self-management education on psychological status and blood glucose in newly diagnosed patients with diabetes type 2. Patient Education and Counseling, 2018, 101, 1427-1432.	2.2	40
58	<scp>C</scp>hina type 2 diabetes treatment status survey of treatment pattern of oral drugs users. Journal of Diabetes, 2015, 7, 166-173.	1.8	39
59	Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. Diabetes Therapy, 2020, 11, 15-35.	2.5	39
60	Relationship Between Gestational Weight Gain and Pregnancy Complications or Delivery Outcome. Scientific Reports, 2017, 7, 12531.	3.3	38
61	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating secondâ€line therapy after metformin monotherapy: <scp>R</scp>etrospective data for 10â€‰256 individuals from the <scp>U</scp>nited <scp>K</scp>ingdom and <scp>G</scp>ermany. Diabetes, Obesity and Metabolism, 2018, 20, 389-399.	4.4	38
62	Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes, Obesity and Metabolism, 2019, 21, 1474-1482.	4.4	38
63	Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis. Experimental Diabetes Research, 2012, 2012, 1-14.	3.8	37
64	Relationship Between Serum Zinc Level and Microvascular Complications in Patients with Type 2 Diabetes. Chinese Medical Journal, 2015, 128, 3276-3282.	2.3	37
65	Human serum acylcarnitine profiles in different glucose tolerance states. Diabetes Research and Clinical Practice, 2014, 104, 376-382.	2.8	35
66	Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 415-420.	4.4	35
67	Association of serum ferritin levels with metabolic syndrome and insulin resistance in a Chinese population. Journal of Diabetes and Its Complications, 2017, 31, 364-368.	2.3	35
68	The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study. Scientific Reports, 2017, 7, 46534.	3.3	34
69	Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in Chinaâ€”Study Design and Baseline Characteristics. Diabetes Technology and Therapeutics, 2015, 17, 735-744.	4.4	33
70	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics, 2017, 39, 1780-1789.e33.	2.5	33
71	Type 1 diabetes stigma in China: A call to end the devaluation of individuals living with a manageable chronic disease. Diabetes Research and Clinical Practice, 2015, 107, 306-307.	2.8	32
72	Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study. Diabetes Care, 2017, 40, 253-260.	8.6	32

#	Article	IF	Citations
73	Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilateâ€"Free Radical Scavenger and Growth Factor Inhibition. BioMed Research International, 2017, 2017, 1-11.	1.9	32
74	SGLT2 inhibitors and lower limb complications: an updated metaâ€analysis. Cardiovascular Diabetology, 2021, 20, 91.	6.8	32
75	Brain derived neurotrophic factor in newly diagnosed diabetes and prediabetes. Molecular and Cellular Endocrinology, 2016, 429, 106-113.	3.2	31
76	Association between Family History Risk Categories and Prevalence of Diabetes in Chinese Population. PLoS ONE, 2015, 10, e0117044.	2.5	31
77	Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study. PLoS ONE, 2016, 11, e0144179.	2.5	31
78	Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial. PLoS ONE, 2013, 8, e57222.	2.5	30
79	Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study. Journal of Diabetes and Its Complications, 2018, 32, 150-156.	2.3	30
80	Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study. Journal of Diabetes Investigation, 2019, 10, 539-551.	2.4	30
81	Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes and Metabolism Journal, 2020, 44, 11.	4.7	30
82	Dietary patterns associated with HbA1c and LDL cholesterol among individuals with type 1 diabetes in China. Journal of Diabetes and Its Complications, 2015, 29, 343-349.	2.3	29
83	Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease. Journal of Diabetes Investigation, 2014, 5, 464-471.	2.4	28
84	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care, 2015, 38, 1627-1633.	8.6	28
85	Efficacy and Safety of Initial Combination Therapy in Treatment-NaÃ¯ve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Therapy, 2018, 9, 1995-2014.	2.5	28
86	Type 1 diabetes mellitus care and education in China: The 3C study of coverage, cost, and care in Beijing and Shantou. Diabetes Research and Clinical Practice, 2017, 129, 32-42.	2.8	27
87	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase Iâ€"<scp>III</scp> clinical trials. Journal of Diabetes Investigation, 2019, 10, 418-428.	2.4	27
88	Risk prediction model of gestational diabetes mellitus based on nomogram in a Chinese population cohort study. Scientific Reports, 2020, 10, 21223.	3.3	27
89	Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 1789-1798.	1.8	26
90	Prevalence of Metabolic Syndrome and Its Determinants in Newly-Diagnosed Adult-Onset Diabetes in China: A Multi-Center, Cross-Sectional Survey. Frontiers in Endocrinology, 2019, 10, 661.	3.5	26

#	Article	IF	Citations
91	Relationship between anti-thyroid peroxidase antibody positivity and pregnancy-related and fetal outcomes in Euthyroid women: a single-center cohort study. BMC Pregnancy and Childbirth, 2020, 20, 491.	2.4	26
92	Obesity-Related Genomic Loci Are Associated with Type 2 Diabetes in a Han Chinese Population. PLoS ONE, 2014, 9, e104486.	2.5	25
93	Independent markers of nonalcoholic fatty liver disease in a gentrifying populationâ€based Chinese cohort. Diabetes/Metabolism Research and Reviews, 2019, 35, e3156.	4.0	25
94	A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population. Genetics in Medicine, 2019, 21, 939-947.	2.4	25
95	Validation of the Swedish Diabetes Re-Grouping Scheme in Adult-Onset Diabetes in China. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3519-e3528.	3.6	25
96	Comparisons of the Efficacy of Alpha Glucosidase Inhibitors on Type 2 Diabetes Patients between Asian and Caucasian. PLoS ONE, 2013, 8, e79421.	2.5	24
97	Elevated serum ferritin concentration is associated with incident type 2 diabetes mellitus in a Chinese population: A prospective cohort study. Diabetes Research and Clinical Practice, 2018, 139, 155-162.	2.8	24
98	Regional Differences in the Prevalence of Coronary Heart Disease and Stroke in Patients With Type 2 Diabetes in China. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3319-3330.	3.6	24
99	Identification of autoimmune type 1 diabetes and multiple organâ€specific autoantibodies in adultâ€onset nonâ€insulinâ€requiring diabetes in China: A populationâ€based multicentre nationwide survey. Diabetes, Obesity and Metabolism, 2019, 21, 893-902.	4.4	24
100	Early life exposure to 1959â€1961 Chinese famine exacerbates association between diabetes and cardiovascular disease. Journal of Diabetes, 2020, 12, 134-141.	1.8	24
101	Effectiveness of different waist circumference cut-off values in predicting metabolic syndrome prevalence and risk factors in adults in China. Biomedical and Environmental Sciences, 2014, 27, 325-34.	0.2	24
102	Randomized clinical trial of the safety and efficacy of sitagliptin and metformin coâ€administered to Chinese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2016, 7, 727-736.	2.4	23
103	Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians. Journal of Hypertension, 2016, 34, 1648-1653.	0.5	23
104	Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1527-1541.	2.4	23
105	IBI362Â(LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine, 2021, 39, 101088.	7.1	23
106	Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1548-1556.	3.6	22
107	Use of sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. Diabetes, Obesity and Metabolism, 2019, 21, 2354-2367.	4.4	22
108	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagonâ€Like Peptideâ€1 Receptor Agonist and Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e015323.	3.7	22

#	Article	IF	Citations
109	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2016, 11, e0154206.	2.5	22
110	The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999â€“2004. Nutrients, 2022, 14, 1224.	4.1	22
111	Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study. Journal of Diabetes and Its Complications, 2016, 30, 1609-1613.	2.3	21
112	Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: effect of folic acid intervention. American Journal of Clinical Nutrition, 2017, 105, 564-570.	4.7	21
113	Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. Journal of Diabetes Research, 2019, 2019, 1-10.	2.3	21
114	Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. PLoS ONE, 2016, 11, e0166625.	2.5	21
115	Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Science China Life Sciences, 2017, 60, 225-238.	4.9	20
116	Glycaemic control in patients with type 2 diabetes initiating secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2020, 22, 66-78.	4.4	20
117	Use of sodiumâ€glucose coâ€transporterâ€2 inhibitors in <scp>Asian</scp> patients with type 2 diabetes and kidney disease: An <scp>Asian</scp> perspective and expert recommendations. Diabetes, Obesity and Metabolism, 2021, 23, 299-317.	4.4	20
118	Age at Diagnosis and C-Peptide Level Are Associated with Diabetic Retinopathy in Chinese. PLoS ONE, 2014, 9, e91174.	2.5	20
119	Comparisons of the efficacy of glucose control, lipid profile, and Î²-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. Endocrine, 2015, 50, 590-597.	2.3	19
120	Addition of dipeptidyl peptidaseâ€4 inhibitors to insulin treatment in type 2 diabetes patients: A metaâ€analysis. Journal of Diabetes Investigation, 2018, 9, 813-821.	2.4	19
121	Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of Medical Economics, 2019, 22, 336-343.	2.1	19
122	The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study. Scientific Reports, 2019, 9, 7709.	3.3	19
123	Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. Scientific Reports, 2019, 9, 12086.	3.3	18
124	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial with a focus on Asia. Diabetes, Obesity and Metabolism, 2021, 23, 1886-1891.	4.4	18
125	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, Volume 9, 243-249.	2.4	17
126	Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review. Journal of Diabetes Investigation, 2017, 8, 518-534.	2.4	17

#	Article	IF	Citations
127	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINAÂ® trial. Diabetology International, 2020, 11, 129-141.	1.4	17
128	Efficacy and safety of insulin glargine 300â€‰U/mL versus insulin glargine 100â€‰U/mL in Asia Pacific insulinâ€naÃ¯ve people with type 2 diabetes: The EDITION AP randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 612-621.	4.4	17
129	Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey. Chinese Medical Journal, 2014, 127, 3524-9.	2.3	17
130	Shortâ€term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. Diabetes/Metabolism Research and Reviews, 2015, 31, 537-544.	4.0	16
131	The Association of Retinopathy and Plasma Glucose and HbA1c: A Validation of Diabetes Diagnostic Criteria in a Chinese Population. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	16
132	Efficacy and safety of fixedâ€dose combination therapy, alogliptin plus metformin, in <scp>A</scp>sian patients with type 2 diabetes: <scp>A</scp> phase 3 trial. Diabetes, Obesity and Metabolism, 2017, 19, 754-758.	4.4	16
133	Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. Journal of Diabetes, 2017, 9, 787-799.	1.8	16
134	Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetesâ€"A multicenter cross-sectional observational study across China. PLoS ONE, 2019, 14, e0216151.	2.5	16
135	Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An<scp>East Asian</scp>perspective. Diabetes, Obesity and Metabolism, 2021, 23, 3-17.	4.4	16
136	National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. Diabetes Therapy, 2015, 6, 519-530.	2.5	15
137	Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-NaÃ¯ve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial. Advances in Therapy, 2015, 32, 201-215.	2.9	15
138	Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes. Scientific Reports, 2016, 6, 36437.	3.3	15
139	Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China. Journal of Diabetes and Its Complications, 2018, 32, 1000-1005.	2.3	15
140	Prevalence, treatment patterns and control rates of metabolic syndrome in a Chinese diabetic population: China Cardiometabolic Registries 3B study. Journal of Diabetes Investigation, 2018, 9, 789-798.	2.4	15
141	Cigarette Smoking Is Associated with a Lower Prevalence of Newly Diagnosed Diabetes Screened by OGTT than Non-Smoking in Chinese Men with Normal Weight. PLoS ONE, 2016, 11, e0149234.	2.5	15
142	Silent myocardial ischemia detected by single photon emission computed tomography (SPECT) and risk of cardiac events among asymptomatic patients with type 2 diabetes: A meta-analysis of prospective studies. Journal of Diabetes and Its Complications, 2014, 28, 413-418.	2.3	14
143	Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China. Diabetes Technology and Therapeutics, 2015, 17, 816-824.	4.4	14
144	DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis. Diabetes Technology and Therapeutics, 2016, 18, 784-793.	4.4	14

#	Article	IF	Citations
145	Relationship between healthy lifestyle behaviors and cardiovascular risk factors in Chinese patients with type 2 diabetes mellitus: a subanalysis of the CCMR-3B STUDY. Acta Diabetologica, 2017, 54, 569-579.	2.5	14
146	Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatmentâ€naÃ¯ve Chinese patients: Analysis of results from the CONSENT trial. Diabetes, Obesity and Metabolism, 2018, 20, 1006-1013.	4.4	14
147	Eligibility of patients with type 2 diabetes for sodiumâ€“glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. BMJ Open Diabetes Research and Care, 2019, 7, e000627.	2.8	14
148	Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues, 2019, 18, 36-46.	1.2	14
149	Insulin glargine/lixisenatide fixedâ€ratio combination (<scp>iGlarLixi</scp>) compared with premix or addition of mealâ€time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 2179-2188.	4.4	14
150	Type 1 diabetes induced by immune checkpoint inhibitors. Chinese Medical Journal, 2020, 133, 2595-2598.	2.3	14
151	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes Therapy, 2020, 11, 2629-2645.	2.5	14
152	Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. Journal of Clinical Hypertension, 2020, 22, 212-220.	2.0	14
153	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. American Heart Journal, 2022, 243, 232-239.	2.7	14
154	Simple tests to screen for diabetic peripheral neuropathy. The Cochrane Library, 0, , .	2.8	13
155	Association between serum thyrotropin within the euthyroid range and obesity. Endocrine Journal, 2019, 66, 451-457.	1.6	13
156	Dipeptidyl peptidaseâ€4 inhibitor treatment and the risk of bullous pemphigoid and skinâ€related adverse events: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2021, 37, e3391.	4.0	13
157	Decreased Glycemic Difference Between Diabetes and Nondiabetes in the Elderly Leads to the Reduced Diagnostic Accuracy of Hemoglobin A1c for Diabetes Screening in an Aged Chinese Population. Diabetes Technology and Therapeutics, 2016, 18, 226-232.	4.4	12
158	HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications. Lipids in Health and Disease, 2016, 15, 76.	3.0	12
159	Structured selfâ€monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS. Journal of Diabetes, 2017, 9, 495-501.	1.8	12
160	Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study. Scientific Reports, 2017, 7, 12648.	3.3	12
161	Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. Journal of Diabetes Research, 2017, 2017, 1-11.	2.3	12
162	Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. Diabetes, Obesity and Metabolism, 2019, 21, 2349-2353.	4.4	12

#	Article	IF	Citations
163	Chinese Famine and the diabetes mellitus epidemic. Nature Reviews Endocrinology, 2020, 16, 123-123.	9.6	12
164	The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. Mediators of Inflammation, 2021, 2021, 1-12.	3.0	12
165	Clinical Characteristics of Young Type 2 Diabetes Patients with Atherosclerosis. PLoS ONE, 2016, 11, e0159055.	2.5	12
166	Comparative effectiveness and safety of different basal insulins in a realâ€world setting. Diabetes, Obesity and Metabolism, 2017, 19, 1116-1126.	4.4	11
167	Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with longâ€term type 2 diabetes: A crossâ€sectional survey in China. Diabetes/Metabolism Research and Reviews, 2018, 34, e2960.	4.0	11
168	Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-6.	2.3	11
169	Association between physical activity and abnormal glucose metabolismâ€"A population-based cross-sectional study in China. Journal of Diabetes and Its Complications, 2018, 32, 746-752.	2.3	11
170	Blood glucose profiles in East Asian and Caucasian injectionâ€naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis. Diabetes/Metabolism Research and Reviews, 2018, 34, e3062.	4.0	11
171	Associations of Bone Mineral Density and Bone Metabolism Indices with Urine Albumin to Creatinine Ratio in Chinese Patients with Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 6, 50-55.	1.2	11
172	Prevalence of Thyroid Dysfunction in a Chinese Population with Different Glucose Intolerance Status: A Community-Based Cross-Sectional Study . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4361-4368.	2.4	11
173	Factors associated with glycemic control in typeÂ1 diabetes patients in China: A crossâ€sectional study. Journal of Diabetes Investigation, 2020, 11, 1575-1582.	2.4	11
174	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 39-48.	4.4	11
175	P38 Plays an Important Role in Glucolipotoxicity-Induced Apoptosis in INS-1 Cells. Journal of Diabetes Research, 2014, 2014, 1-7.	2.3	10
176	Analysis of the Associations between Vitamin D and Albuminuria orÎ²-Cell Function in Chinese Type 2 Diabetes. BioMed Research International, 2014, 2014, 1-5.	1.9	10
177	Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Research and Care, 2019, 7, e000728.	2.8	10
178	Loss of HNF1Î± Function Contributes to Hepatocyte Proliferation and Abnormal Cholesterol Metabolism via Downregulating miR-122: A Novel Mechanism of MODY3 . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 627-639.	2.4	10
179	Type 2 diabetes and heart failure: insights from the global DISCOVER study. ESC Heart Failure, 2021, 8, 1711-1716.	3.1	10
180	The Urinary Glucose Excretion by Sodiumâ€"Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 814074.	3.5	10

#	Article	IF	Citations
181	Diabetes awareness, treatment, control rates and associated risk factors among Beijing residents in 2011: A crossâ€sectional survey. Chronic Diseases and Translational Medicine, 2016, 2, 147-158.	1.2	9
182	Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, 137-142.	3.6	9
183	Saxagliptin addâ€on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1044-1049.	4.4	9
184	Insulin Injection Technique in China Compared with the Rest of the World. Diabetes Therapy, 2018, 9, 2357-2368.	2.5	9
185	Chinese clinical guidelines for continuous glucose monitoring (2018 edition). Diabetes/Metabolism Research and Reviews, 2019, 35, e3152.	4.0	9
186	Evaluation of effectiveness of treatment paradigm for newly diagnosed typeÂ2 diabetes patients in Chin: A nationwide prospective cohort study. Journal of Diabetes Investigation, 2020, 11, 151-161.	2.4	9
187	The Prevalence of Osteoporosis Tested by Quantitative Computed Tomography in Patients With Different Glucose Tolerances. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 201-209.	3.6	9
188	Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine, 2020, 70, 232-242.	2.3	9
189	Genetic variants of ABCC8 and phenotypic features in Chinese early onset diabetes. Journal of Diabetes, 2021, 13, 542-553.	1.8	9
190	Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients. Endocrine Practice, 2022, 28, 304-309.	2.1	9
191	Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with TypeÂ1 and Patients with TypeÂ2 Diabetes in China. Diabetes Therapy, 2021, 12, 3079-3092.	2.5	9
192	Impact of microâ€and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. Endocrinology, Diabetes and Metabolism, 2022, 5, e00321.	2.4	9
193	Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. Diabetes Therapy, 2022, 13, 829-846.	2.5	9
194	Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovascular Diabetology, 2013, 12, 118.	6.8	8
195	Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 586-593.	4.4	8
196	Non-linear associations of risk factors with mild hypoglycemia among Chinese patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 462-468.	2.3	8
197	The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients. Clinical Proteomics, 2017, 14, 19.	2.1	8
198	Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China. Frontiers in Endocrinology, 2018, 9, 639.	3.5	8

#	Article	IF	Citations
199	A culturally sensitive nurseâ€led structured education programme in patients with type 2 diabetes. International Journal of Nursing Practice, 2019, 25, e12757.	1.7	8
200	A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients. Journal of Clinical Hypertension, 2019, 21, 1654-1663.	2.0	8
201	The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis. Pharmacological Research, 2020, 161, 105216.	7.1	8
202	The Association Between Serum Thyrotropin Within the Reference Range and Metabolic Syndrome in a Community-Based Chinese Population . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 2001-2011.	2.4	8
203	Achieving Effective and Efficient Basal Insulin Optimal Management by Using Mobile Health Application (APP) for Type 2 Diabetes Patients in China . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1327-1338.	2.4	8
204	PhaseÂIII, randomized, doubleâ€blind, placeboâ€controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with typeÂ2 diabetes mellitus inadequately controlled with diet and exercise. Journal of Diabetes Investigation, 2021, 12, 537-545.	2.4	8
205	Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1956-1960.	4.4	8
206	Urinary Câ€peptide/creatinine ratio: A useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. Journal of Diabetes, 2021, 13, 893-904.	1.8	8
207	Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System. Journal of Diabetes Science and Technology, 2023, 17, 208-213.	2.2	8
208	Clinical and Genetic Characteristics of ABCC8 Nonneonatal Diabetes Mellitus: A Systematic Review. Journal of Diabetes Research, 2021, 2021, 1-14.	2.3	8
209	ACEI/ARB Underused in Patients with Type 2 Diabetes in Chinese Population (CCMR-3B Study). PLoS ONE, 2015, 10, e0116970.	2.5	8
210	The Effect of Physical Activity on Glycemic Variability in Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2021, 12, 767152.	3.5	8
211	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	6.8	8
212	Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors. Diabetes Technology and Therapeutics, 2017, 19, 675-684.	4.4	7
213	Characteristics and Ongoing Autoimmunity of Patients With Long-standing Type 1 Diabetes Living in China. Diabetes Care, 2018, 41, e97-e98.	8.6	7
214	The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China. BMC Health Services Research, 2018, 18, 300.	2.2	7
215	Characteristics of Newly Diagnosed Type 2 Diabetes in Chinese Older Adults: A National Prospective Cohort Study. Journal of Diabetes Research, 2019, 2019, 1-9.	2.3	7
216	Urinary C-Peptide Creatinine Ratio as a Non-Invasive Tool for Identifying Latent Autoimmune Diabetes in Adults (LADA) . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2531-2537.	2.4	7

#	Article	IF	Citations
217	Simple-to-use nomogram for evaluating the incident risk of moderate-to-severe LEAD in adults with type 2 diabetes: A cross-sectional study in a Chinese population. Scientific Reports, 2020, 10, 3182.	3.3	7
218	Higher versus standard starting dose of insulin glargine 100â€‰U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, openâ€label, randomized controlled trial (BEYOND VII). Diabetes, Obesity and Metabolism, 2020, 22, 838-846.	4.4	7
219	New clinical screening strategy to distinguish HNF1A variant-induced diabetes from young early-onset type 2 diabetes in a Chinese population. BMJ Open Diabetes Research and Care, 2020, 8, e000745.	2.8	7
220	Associations between secondâ€line glucoseâ€lowering combination therapies with metformin and <scp>HbA1c</scp>, body weight, quality of life, hypoglycaemic events and glucoseâ€lowering treatment intensification: The <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1823-1833.	4.4	7
221	Comparison of the dietary intakes of individuals with and without type 1 diabetes in China. Asia Pacific Journal of Clinical Nutrition, 2015, 24, 639-49.	0.4	7
222	Non-pharmaceutical factors for poor glycemic control in 13,970 Chinese women with drug-treated type 2 diabetes: a cross-sectional survey in 77 tertiary hospitals in four Chinese cities. Patient Preference and Adherence, 2014, 8, 1161.	1.8	6
223	IL-1Brs1143623 andEEF1A1P11-RPL7P9rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. Pharmacogenomics, 2015, 16, 1621-1629.	1.3	6
224	Effectiveness of clinical alternatives to nerve conduction studies for screening for diabetic distal symmetrical polyneuropathy: A multi-center study. Diabetes Research and Clinical Practice, 2016, 115, 150-156.	2.8	6
225	Uric acid, renal function and risk of hypoglycaemia in Chinese type 2 diabetes patients. Diabetes/Metabolism Research and Reviews, 2016, 32, 875-882.	4.0	6
226	Prevalence of and risk factors for diabetic ketosis in Chinese diabetic patients with random blood glucose levels >13.9 mmol/L: Results from the CHina study in prEvalence of diabetiC Ketosis (CHECK) study. Journal of Diabetes, 2018, 10, 249-255.	1.8	6
227	Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension. Diabetology and Metabolic Syndrome, 2019, 11, 69.	2.7	6
228	Albuminuria and other target organ damage in Chinese patients with hypertension and diabetes: A data analysis based on the ATTEND study. Journal of Diabetes and Its Complications, 2020, 34, 107470.	2.3	6
229	Is visceral abdominal fat area a better indicator for hyperglycemic risk? Results from the Pinggu Metabolic Disease Study. Journal of Diabetes Investigation, 2020, 11, 888-895.	2.4	6
230	Patient characteristics and 6â€month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). Journal of Diabetes, 2020, 12, 668-676.	1.8	6
231	Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, doubleâ€blind, placeboâ€controlled study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00222.	2.4	6
232	Chinese clinical practice guidelines for perioperative blood glucose management. Diabetes/Metabolism Research and Reviews, 2021, 37, e3439.	4.0	6
233	What are the factors associated with longâ€term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (â‰¥7.0%) at initiation of secondâ€line therapy? Results from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 2336-2343.	4.4	6
234	Association Between Iodine Nutritional Status and Adverse Pregnancy Outcomes in Beijing, China: a Single-Center Cohort Study. Biological Trace Element Research, 2022, 200, 2620-2628.	3.5	6

#	Article	IF	Citations
235	A Deep Reinforcement Learning Approach for Type 2 Diabetes Mellitus Treatment. , 2020, , .		6
236	Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes. BioMed Research International, 2015, 2015, 1-8.	1.9	5
237	Predictors of Renal Function Decline in Chinese Patients with Type 2 Diabetes Mellitus and in a Subgroup of Normoalbuminuria: A Retrospective Cohort Study. Diabetes Technology and Therapeutics, 2016, 18, 635-643.	4.4	5
238	Plasma NT-proBNP is independently associated with albuminuria in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 669-674.	2.3	5
239	Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population. Journal of Diabetes Research, 2017, 2017, 1-5.	2.3	5
240	Gender Difference in the Association of Early- vs. Late-Onset Type 2 Diabetes with Non-Fatal Microvascular Disease in China: A Cross-sectional Study. Frontiers in Endocrinology, 2018, 9, 15.	3.5	5
241	Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial. Advances in Therapy, 2018, 35, 864-874.	2.9	5
242	Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, openâ€label, randomized controlled clinical study. Diabetes, Obesity and Metabolism, 2020, 22, 158-166.	4.4	5
243	Age, sex, disease severity, and diseaseÂduration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine, 2020, 18, 322.	5.5	5
244	Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
245	A pragmatic study of midâ€mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from realâ€world experience. Diabetes, Obesity and Metabolism, 2020, 22, 1436-1442.	4.4	5
246	Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like PeptideÂ1 Receptor Agonists in Chinese Patients with TypeÂ2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1861-1870.	2.5	5
247	Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes and Metabolism Journal, 2021, 45, 312-325.	4.7	5
248	Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study. Journal of Clinical Hypertension, 2021, 23, 1399-1404.	2.0	5
249	SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis. European Journal of Pharmacology, 2021, 903, 174145.	3.5	5
250	Genetics and Clinical Characteristics of PPARÎ³ Variant-Induced Diabetes in a Chinese Han Population. Frontiers in Endocrinology, 2021, 12, 677130.	3.5	5
251	Screening strategy for islet autoantibodies in diabetes patients of different ages. Diabetes Technology and Therapeutics, 2021, , .	4.4	5
252	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naÃ¯ve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial. EClinicalMedicine, 2021, 42, 101185.	7.1	5

#	Article	IF	Citations
253	GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY). Frontiers in Immunology, 2022, 13, 836952.	4.8	5
254	Association Between Indices of Body Composition and Metabolically Unhealthy Phenotype in China: A Cross-Sectional Study. Frontiers in Endocrinology, 2022, 13, .	3.5	5
255	The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 2022, 15, 877-886.	3.1	5
256	Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China. Journal of Endocrinological Investigation, 2014, 37, 843-852.	3.3	4
257	Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects. Journal of Diabetes, 2017, 9, 1091-1099.	1.8	4
258	Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 449-453.	1.2	4
259	Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes. Journal of Diabetes Research, 2019, 2019, 1-8.	2.3	4
260	Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. , 2019, 10, 1311.		4
261	Search for clinical predictors of good glycemic control in patients starting or intensifying oral hypoglycemic pharmacological therapy: A multicenter prospective cohort study. Journal of Diabetes and Its Complications, 2020, 34, 107464.	2.3	4
262	Erythrocytosis and Performance of HbA1c in Detecting Diabetes on an Oxygen-Deficient Plateau: A Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1612-e1620.	3.6	4
263	A multicenter all-inclusive prospective study on the relationship between glycemic control markers and maternal and neonatal outcomes in pregnant women. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3154-3161.	1.5	4
264	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2020, 165, 108250.	2.8	4
265	Sex-influenced association of metabolic syndrome with lower extremity arterial disease in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107537.	2.3	4
266	Greater macrovascular and microvascular morbidity from typeÂ2 diabetes in northern compared with southern China: A crossâ€sectional study. Journal of Diabetes Investigation, 2020, 11, 1285-1294.	2.4	4
267	Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus. Endocrinology, Diabetes and Metabolism, 2020, 3, e00122.	2.4	4
268	Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107750.	2.3	4
269	Sex differences in the prevalence of obesity in 800,000 Chinese adults with type 2 diabetes. Endocrine Connections, 2021, 10, 139-145.	1.9	4
270	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. BMJ Open Diabetes Research and Care, 2021, 9, e001585.	2.8	4

#	Article	IF	Citations
271	A case report of pseudohypoaldosteronism type II with a homozygous KLHL3 variant accompanied by hyperthyroidism. BMC Endocrine Disorders, 2021, 21, 103.	2.2	4
272	Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies. Diabetes Research and Clinical Practice, 2021, 176, 108848.	2.8	4
273	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Research and Clinical Practice, 2021, 177, 108870.	2.8	4
274	The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial. Advances in Clinical and Experimental Medicine, 2017, 26, 671-677.	1.4	4
275	The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2020, 11, 541699.	3.5	4
276	The Effects of Supervised Exercise Training on Weight Control and Other Metabolic Outcomes in Patients With Type 2 Diabetes: A Meta-Analysis. International Journal of Sport Nutrition and Exercise Metabolism, 2022, 32, 186-194.	2.1	4
277	Quality of life in people with type 2 diabetes in the 3Âyears following initiation of second-line therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2022, 185, 109218.	2.8	4
278	Hereditary renal glycosuria, diabetes and responses to <scp>SGLT2</scp> inhibitor. Journal of Diabetes, 2022, 14, 216-220.	1.8	4
279	Increasing body mass index identifies Chinese patients with type 2 diabetes mellitus at risk of poor outcomes. Journal of Diabetes and Its Complications, 2015, 29, 488-496.	2.3	3
280	Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients. Chinese Medical Journal, 2018, 131, 1605-1612.	2.3	3
281	Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The) Tj ETQq1 1 0.784314 rgBT/Overlock	2.9	3
282	A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes. Journal of Diabetes Research, 2019, 2019, 1-6.	2.3	3
283	Association Between Abnormal Glycemic Phenotypes and Microvascular Complications of Type 2 Diabetes Mellitus Outpatients in China . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4651-4659.	2.4	3
284	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open, 2020, 10, e034613.	1.9	3
285	The effect of education and mobile health management on improvement of blood glucose with type 2 diabetes mellitus. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 205-209.	1.6	3
286	The impact of ferritin on the disassociation of HbA1c and mean plasma glucose. Journal of Diabetes, 2021, 13, 512-520.	1.8	3
287	Flash glucose monitoring data analysed by detrended fluctuation function on betaâ€cell function and diabetes classification. Diabetes, Obesity and Metabolism, 2021, 23, 774-781.	4.4	3
288	Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population. Diabetes, 2021, 70, 809-816.	0.6	3

#	Article	IF	Citations
289	A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 745-755.	0.7	3
290	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. Diabetes Research and Clinical Practice, 2021, 178, 108947.	2.8	3
291	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2021, 35, 107980.	2.3	3
292	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2021, 180, 108974.	2.8	3
293	Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone. Chinese Medical Journal, 2015, 128, 1279-1287.	2.3	3
294	Cardiovascular benefits beyond urinary glucose excretion: <scp>A hypothesis generated from two metaâ€analyses</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 550-554.	4.4	3
295	A variation in SORBS1 is associated with type 2 diabetes and highâ€density lipoprotein cholesterol in Chinese population. Diabetes/Metabolism Research and Reviews, 2022, 38, e3524.	4.0	3
296	Expert consensus on personalized initiation of glucoseâ€lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. Journal of Evidence-Based Medicine, 2022, 15, 168-179.	1.8	3
297	Hyperglycemia and Blood Pressure Treatment Goal: A Cross Sectional Survey of 18350 Patients with Type 2 Diabetes in 77 Tertiary Hospitals in China. PLoS ONE, 2014, 9, e103507.	2.5	2
298	Sex disparity in the risk of diabetes-associated stroke. Lancet, The, 2014, 383, 1948-1950.	13.7	2
299	Determinants of poor glycemic control in Chinese men with type 2 diabetes: a cross-sectional survey of 15,427 men in 77 tertiary hospitals in China. International Journal of Diabetes in Developing Countries, 2015, 35, 488-492.	0.8	2
300	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. Expert Opinion on Pharmacotherapy, 2016, 17, 1591-1598.	1.8	2
301	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2017, 37, 1107-1115.	2.2	2
302	Clinical characteristics of type 2 diabetes patients with discordance between <scp>HbA_{1c}</scp> and fasting plasma glucose in the real world: <scp>A</scp>n analysis of the <scp>ORBIT</scp> study. Diabetes/Metabolism Research and Reviews, 2018, 34, e2977.	4.0	2
303	The global impact of the International Federation of Clinical Chemistry and Laboratory Medicine, Education and Management Division: engaging stakeholders and assessing HbA_{1c} quality in a multicentre study across China. Clinical Chemistry and Laboratory Medicine, 2018, 57, 288-295.	2.3	2
304	Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis. Diabetes Technology and Therapeutics, 2018, 20, 704-714.	4.4	2
305	The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. Metabolic Syndrome and Related Disorders, 2020, 18, 284-290.	1.3	2
306	Silent hemoglobin variant during capillary electrophoresis: A case report. Journal of Diabetes Investigation, 2020, 11, 1014-1017.	2.4	2

#	Article	IF	Citations
307	Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Gravesâ€™ Disease From Autoimmune Thyroiditis. Frontiers in Endocrinology, 2020, 11, 620407.	3.5	2
308	Age-stratified association of blood pressure with albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes mellitus. Blood Pressure, 2021, 30, 180-187.	1.5	2
309	Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study. Diabetologia, 2021, 64, 1066-1078.	6.3	2
310	Development and validation of a risk score model for prediction of lower extremity arterial disease in Chinese with type 2 diabetes aged over 50 years. Endocrine Connections, 2021, 10, 1212-1220.	1.9	2
311	Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opinion on Drug Safety, 2022, 21, 425-434.	2.4	2
312	Treatment Effects of Short-Term Continuous Positive Airway Pressure on Blood Glucose Control in Type 2 Diabetic Patients with Obstructive Sleep Apnea Syndrome . International Journal of General Medicine, 2020, Volume 13, 1567-1573.	1.8	2
313	A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. Journal of Diabetes Research, 2022, 2022, 1-10.	2.3	2
314	Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis. Biomedical and Environmental Sciences, 2020, 33, 37-47.	0.2	2
315	Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.	2.2	2
316	Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis. Endocrine, 2022, 77, 205-212.	2.3	2
317	Status of basalâ€supported oral therapy in Chinese type 2 diabetic patients with inadequate glycemic control on oral antiâ€diabetic drugs. Diabetes/Metabolism Research and Reviews, 2015, 31, 796-802.	4.0	1
318	A Novel Mutation of PRKAR1A Caused Carney Complex in a Chinese Patient. Chinese Medical Journal, 2017, 130, 3009-3010.	2.3	1
319	Long exposure to type 2 diabetes and risk of non-fatal coronary heart disease in Chinese females and males: Findings from a China national cross-sectional study. Diabetes Research and Clinical Practice, 2018, 137, 119-127.	2.8	1
320	A Screening Approach for Mitochondrial tRNALeu(UUR) A3243G Mutation in a Hospital-Based Population with Diabetes. Chinese Medical Journal, 2018, 131, 1117-1119.	2.3	1
321	Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China. Diabetes Technology and Therapeutics, 2018, 20, 825-832.	4.4	1
322	Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study. Journal of Diabetes Research, 2019, 2019, 1-5.	2.3	1
323	Factors Associated with Acute Complications among Individuals with Type 1 Diabetes in China: The 3C Study. Endocrine Research, 2020, 45, 1-8.	1.2	1
324	Prevalence of Albuminuria in Cardiology and Endocrinology Departments and Its Influencing Factors: A Multicenter, Real-World Evidence Study in China. International Journal of Hypertension, 2020, 2020, 1-7.	1.3	1

#	Article	IF	Citations
325	A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients. Diabetes Therapy, 2021, 12, 1887-1899.	2.5	1
326	Do East Asians With Normal Glucose Tolerance Have Worse Î²-Cell Function? A Meta-Analysis of Epidemiological Studies. Frontiers in Endocrinology, 2021, 12, 780557.	3.5	1
327	Trends and regional differences in glycemic control of patients with type 2 diabetes in China, 2009â€“2013. Chinese Medical Journal, 2022, 135, 1637-1638.	2.3	1
328	An Update on Animal Models of Osteogenesis Imperfecta. Calcified Tissue International, 0, , .	3.1	1
329	662 A/G gene variation in human tumor necrosis factor receptor superfamily, member 9 (TNFRSF9). Frontiers of Medicine in China, 2008, 2, 283-285.	0.1	0
330	Hb broomhill [Î±1 or Î±2 114(GH2) proâ€‰>â€‰ala;HBA1 or HBA2:c.343Câ€‰>â€‰G]: a rare Hb variant found in a diabetic chinese individual. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 606-609.	1.2	0
331	Cover Image, Volume 22, Issue 5. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
332	Response to â€œDenosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysisâ€• Bone, 2020, 134, 115271.	2.9	0
333	A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience. Diabetes Therapy, 2021, 12, 931-941.	2.5	0
334	Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study. Diabetes Therapy, 2021, 12, 2359-2369.	2.5	0
335	Characteristics, treatment patterns, and glycemic control of older type 2 diabetes mellitus patients in China. Chinese Medical Journal, 2021, Publish Ahead of Print, 2893-2895.	2.3	0
336	Cardiovascular risk profile and clinical characteristics of diabetic patients. Chinese Medical Journal, 2021, Publish Ahead of Print, .	2.3	0
337	Factors associated with resistance to complications in long-standing type 1 diabetes in China. Endocrine Connections, 2020, 9, 187-193.	1.9	0
338	Reflections on a successful hybrid type 1 diabetes summer camp in China during the COVIDâ€•19 pandemic. Journal of Diabetes, 2022, , .	1.8	0
339	A pituitary abscess with one year follow-up after conservative treatment: A case report. Neuroendocrinology Letters, 2018, 38, 532-536.	0.2	0
340	Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort. Medicine (United States), 2021, 100, e28238.	1.0	0
341	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	4.4	0